Research ArticleCLINICAL INVESTIGATIONS
131I Effective Half-Life and Dosimetry in Thyroid Cancer Patients
Hervé Remy, Isabelle Borget, Sophie Leboulleux, Nadine Guilabert, Frédéric Lavielle, Jérome Garsi, Claire Bournaud, Séverine Gupta, Martin Schlumberger and Marcel Ricard
Journal of Nuclear Medicine September 2008, 49 (9) 1445-1450; DOI: https://doi.org/10.2967/jnumed.108.052464
Hervé Remy
Isabelle Borget
Sophie Leboulleux
Nadine Guilabert
Frédéric Lavielle
Jérome Garsi
Claire Bournaud
Séverine Gupta
Martin Schlumberger
In this issue
Journal of Nuclear Medicine
Vol. 49, Issue 9
September 2008
131I Effective Half-Life and Dosimetry in Thyroid Cancer Patients
Hervé Remy, Isabelle Borget, Sophie Leboulleux, Nadine Guilabert, Frédéric Lavielle, Jérome Garsi, Claire Bournaud, Séverine Gupta, Martin Schlumberger, Marcel Ricard
Journal of Nuclear Medicine Sep 2008, 49 (9) 1445-1450; DOI: 10.2967/jnumed.108.052464
131I Effective Half-Life and Dosimetry in Thyroid Cancer Patients
Hervé Remy, Isabelle Borget, Sophie Leboulleux, Nadine Guilabert, Frédéric Lavielle, Jérome Garsi, Claire Bournaud, Séverine Gupta, Martin Schlumberger, Marcel Ricard
Journal of Nuclear Medicine Sep 2008, 49 (9) 1445-1450; DOI: 10.2967/jnumed.108.052464
Jump to section
Related Articles
Cited By...
- Analysis of Radiometry on Patients Undergoing Radioactive Iodine Therapy
- Thyroid Uptake and Effective Half-Life of Radioiodine in Thyroid Cancer Patients at Radioiodine Therapy and Follow-Up Whole-Body Scintigraphy Either in Hypothyroidism or Under rhTSH
- Recombinant human thyrotropin preparation for adjuvant radioiodine treatment in children and adolescents with differentiated thyroid cancer
- Dosimetry and thyroid cancer: the individual dosage of radioiodine
- Influence of Vitamin C on Salivary Absorbed Dose of 131I in Thyroid Cancer Patients: A Prospective, Randomized, Single-Blind, Controlled Trial